Home > others & > Edaravone

Edaravone

依达拉奉,MCI-186,MCI 186,MCI186

Edaravone是一种强效的新型的自由基清除剂，用于治疗急性脑梗死。

目录号
EY1058
EY1058
纯度
99.43%
99.43%
规格
50 mg
100 mg
原价
135.00
180
售价
135.00
180
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Edaravone is a novel potent free radical scavenger that has been clinically used to reduce the neuronal damage following ischemic stroke.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Yoshida H, et al. CNS Drug Rev, 2006, 12(1), 9-20.

    分子式
    C10H10N2O    		 分子量
    174.2    		 CAS号
    89-25-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    35 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    35 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02644915 Kidney Transplantation Drug: Edaravone|Drug: 0.9%%NaCl solution Xijing Hospital|First Affiliated Hospital Xi'an Jiaotong University 2016-03-01 2015-12-30
    NCT00265239 Myocardial Infarction|Reperfusion Injury Drug: edaravone Kumamoto University|Japan Heart Foundation Phase 4 2001-04-01 2014-09-12
    NCT00821821 Acute Ischemic Stroke (AIS) Drug: MCI-186|Drug: Placebo Mitsubishi Tanabe Pharma Corporation Phase 2 2009-02-01 2014-04-07
    NCT01865201 Nasopharyngeal Carcinoma|Brain Necrosis Drug: Edaravone|Other: Common fundamental management Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 2009-03-01 2013-12-11
    NCT00200356 Cerebral Infarction Drug: Edaravone|Drug: Sodium Ozagrel Mitsubishi Tanabe Pharma Corporation Phase 4 2004-08-01 2012-12-09
    NCT02430350 Acute Ischemic Stroke Drug: Compound Edaravone Injection|Drug: Edaravone Injection Jiangsu Simcere Pharmaceutical Co., Ltd. Phase 3 2015-05-01 2017-01-12
    NCT00330681 Amyotrophic Lateral Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186 Mitsubishi Tanabe Pharma Corporation Phase 3 2006-05-01 2014-09-16
    NCT00415519 Amyotrophic Lateral Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186 Mitsubishi Tanabe Pharma Corporation Phase 3 2006-12-01 2014-09-16
    NCT00424463 Amyotrophic Lateral Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186 Mitsubishi Tanabe Pharma Corporation Phase 3 2007-01-01 2013-02-27
    NCT01929096 Acute Ischemic Stroke Drug: Compound Edaravone Injection|Drug: Edaravone Injection Jiangsu Simcere Pharmaceutical Co., Ltd. Phase 2 2013-08-01 2015-07-01
    NCT00153946 Stroke Drug: Edaravone Combination Therapy for Acute Ischemic Stroke Study Group|Japan Cardiovascular Research Foundation Phase 4 2004-08-01 2008-05-12
    NCT01492686 Amyotrophic Lateral Sclerosis (ALS) Drug: MCI-186|Drug: Placebo|Drug: MCI-186 in open label phase Mitsubishi Tanabe Pharma Corporation Phase 3 2011-12-01 2015-06-18
    NCT01894334 Acute Aortic Dissection Drug: Ulinastatin|Drug: Tranexamic acid|Drug: Edaravone Beijing Anzhen Hospital 2013-04-01 2014-01-23
    NCT01556854 Acute Ischemic Stroke yongjun wang|Ministry of Science and Technology of the Peoples Republic of China 2011-07-01 2012-03-15
    NCT01518231 Stroke Procedure: autologous hematopoiesis stem cell transplantation|Drug: Aspirin|Drug: Warfarin|Drug: Atorvastatin|Drug: Edaravone|Drug: Aspirin|Drug: Warfarin|Drug: Atorvastatin|Drug: Edaravone Zhejiang Hospital|Zhejiang University Phase 1 2012-01-01 2012-01-24

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：